Literature DB >> 8875286

Pyrimethamine alone as prophylaxis for cerebral toxoplasmosis in patients with advanced HIV infection.

H Klinker1, P Langmann, E Richter.   

Abstract

Prophylaxis for toxoplasma encephalitis was performed with pyrimethamine alone (50 mg daily) in 56 patients with advanced HIV infection. Thirty-eight patients were at high risk for toxoplasma encephalitis (CD4+ counts < or = 200/microliter, and presence of serum IgG antibodies to Toxoplasma gondii). The overall treatment period was 697 months (mean 12.5 +/- 12.1). During prophylaxis, only one patient developed toxoplasma encephalitis, four patients discontinued treatment due to adverse reactions. Steady state pyrimethamine plasma concentrations were measured by gas chromatography. Mean plasma level was 1,887 +/- 1,161 ng/ml, during liver enzyme-inducing comedication plasma levels were significantly (p = 0.0001) reduced (1,488 +/- 884 ng/ml versus 1,978 +/- 1,196 ng/ml without comedication). All patients received a folinic acid supplement of 7.5 mg daily. Serum folate levels ranged from 5.7-105 (43.7 +/- 29.2) nmol/l; severe hematological side effects did not occur.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8875286     DOI: 10.1007/bf01743370

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  14 in total

1.  Pyrimethamine concentrations in serum and cerebrospinal fluid during treatment of acute Toxoplasma encephalitis in patients with AIDS.

Authors:  L M Weiss; C Harris; M Berger; H B Tanowitz; M Wittner
Journal:  J Infect Dis       Date:  1988-03       Impact factor: 5.226

2.  Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome. Efficacy of long-term continuous therapy.

Authors:  C Leport; F Raffi; S Matheron; C Katlama; B Regnier; A G Saimot; C Marche; C Vedrenne; J L Vilde
Journal:  Am J Med       Date:  1988-01       Impact factor: 4.965

Review 3.  AIDS commentary. Toxoplasmic encephalitis.

Authors:  B J Luft; J S Remington
Journal:  J Infect Dis       Date:  1988-01       Impact factor: 5.226

4.  Pyrimethamine as primary prophylaxis of toxoplasmic encephalitis in patients infected with human immunodeficiency virus: open study.

Authors:  C Bachmeyer; I Gorin; J Deleuze; J P Morini; J P Escande
Journal:  Clin Infect Dis       Date:  1994-03       Impact factor: 9.079

5.  Toxoplasma gondii serology in HIV-infected patients: the development of central nervous system toxoplasmosis in AIDS.

Authors:  I H Grant; J W Gold; M Rosenblum; D Niedzwiecki; D Armstrong
Journal:  AIDS       Date:  1990-06       Impact factor: 4.177

6.  Central nervous system toxoplasmosis in AIDS patients: efficacy of an intermittent maintenance therapy.

Authors:  E Pedrol; J M González-Clemente; J M Gatell; J Mallolas; J M Miró; F Graus; R Alvarez; J M Mercader; J Berenguer; M T Jiménez de Anta
Journal:  AIDS       Date:  1990-06       Impact factor: 4.177

7.  Primary prophylaxis with pyrimethamine for toxoplasmic encephalitis in patients with advanced human immunodeficiency virus disease: results of a randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS.

Authors:  M A Jacobson; C L Besch; C Child; R Hafner; J P Matts; K Muth; D N Wentworth; J D Neaton; D Abrams; D Rimland
Journal:  J Infect Dis       Date:  1994-02       Impact factor: 5.226

8.  Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS.

Authors:  A Carr; B Tindall; B J Brew; D J Marriott; J L Harkness; R Penny; D A Cooper
Journal:  Ann Intern Med       Date:  1992-07-15       Impact factor: 25.391

9.  Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome.

Authors:  S B Porter; M A Sande
Journal:  N Engl J Med       Date:  1992-12-03       Impact factor: 91.245

10.  High risk of developing toxoplasmic encephalitis in AIDS patients seropositive to Toxoplasma gondii.

Authors:  R Zangerle; F Allerberger; P Pohl; P Fritsch; M P Dierich
Journal:  Med Microbiol Immunol       Date:  1991       Impact factor: 3.402

View more
  4 in total

Review 1.  Prophylaxis of human toxoplasmosis: a systematic review.

Authors:  Senaka Rajapakse; Praveen Weeratunga; Chaturaka Rodrigo; Nipun Lakshitha de Silva; Sumadhya Deepika Fernando
Journal:  Pathog Glob Health       Date:  2017-09-26       Impact factor: 2.894

2.  In vitro generation of novel pyrimethamine resistance mutations in the Toxoplasma gondii dihydrofolate reductase.

Authors:  M G Reynolds; J Oh; D S Roos
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

3.  Pantothenic acid biosynthesis in the parasite Toxoplasma gondii: a target for chemotherapy.

Authors:  Sarmad N Mageed; Fraser Cunningham; Alvin Wei Hung; Hernani Leonardo Silvestre; Shijun Wen; Tom L Blundell; Chris Abell; Glenn A McConkey
Journal:  Antimicrob Agents Chemother       Date:  2014-07-21       Impact factor: 5.191

4.  Evaluation of the effect of pyrimethamine, an anti-malarial drug, on HIV-1 replication.

Authors:  Raphael M Oguariri; Joseph W Adelsberger; Michael W Baseler; Tomozumi Imamichi
Journal:  Virus Res       Date:  2010-08-26       Impact factor: 3.303

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.